Ken Griffin Biomea Fusion, Inc. Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$4.14 - $15.3 $9,936 - $36,720	2,400 Added 5.78%	43,900 $197,000
Q1 2024 May 15, 2024	SELL	$13.92 - $19.5 $288,144 - $403,650	-20,700 Reduced 33.28%	41,500 $620,000
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $249,425 - $590,040	29,800 Added 91.98%	62,200 $903,000
Q3 2023 Nov 14, 2023	SELL	$13.44 - $23.02 $427,392 - $732,036	-31,800 Reduced 49.53%	32,400 $445,000
Q2 2023 Aug 14, 2023	BUY	$21.66 - $41.8 $853,404 - $1.65 Million	39,400 Added 158.87%	64,200 $1.41 Million
Q1 2023 May 15, 2023	BUY	$6.8 - $32.35 $137,360 - $653,470	20,200 Added 439.13%	24,800 $769,000
Q4 2022 Feb 14, 2023	BUY	$6.3 - $11.6 $28,980 - $53,360	4,600 New	4,600 $38,000

120

17.9M

978K

286K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $230M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.